Patents by Inventor Adrian PELIN
Adrian PELIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240229069Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: ApplicationFiled: September 5, 2023Publication date: July 11, 2024Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
-
Publication number: 20240132913Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: ApplicationFiled: September 4, 2023Publication date: April 25, 2024Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
-
Patent number: 11802292Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: GrantFiled: January 4, 2019Date of Patent: October 31, 2023Assignees: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Adrian Pelin, Brian Andrew Keller, Caroline J. Breitbach, Michael F. Burgess, Steven H. Bernstein
-
Publication number: 20230022757Abstract: The disclosure relates to modified vaccinia virus vectors derived from the Copenhagen strain of vaccinia virus, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified Copenhagen-derived vaccinia virus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: March 14, 2022Publication date: January 26, 2023Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: John C. Bell, Fabrice Le Boeuf, Michael S. Huh, Matthew Y. Tang, Brian Andrew Keller, Adrian Pelin
-
Publication number: 20220380799Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: December 20, 2019Publication date: December 1, 2022Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20220056480Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: December 20, 2019Publication date: February 24, 2022Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20200392535Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.Type: ApplicationFiled: January 4, 2019Publication date: December 17, 2020Applicants: OTTAWA HOSPITAL RESEARCH INSTITUTE, TURNSTONE BIOLOGICS CORP.Inventors: John C. BELL, Fabrice LE BOEUF, Michael S. HUH, Matthew Y. TANG, Adrian PELIN, Brian Andrew KELLER, Caroline J. BREITBACH, Michael F. BURGESS, Steven H. BERNSTEIN
-
Publication number: 20200385758Abstract: The disclosure relates to modified vaccinia virus vectors derived from the Copenhagen strain of vaccinia virus, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified Copenhagen-derived vaccinia virus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.Type: ApplicationFiled: January 4, 2019Publication date: December 10, 2020Applicant: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: John C. BELL, Fabrice LE BOEUF, Michael S. HUH, Matthew Y. TANG, Brian Andrew KELLER, Adrian PELIN